What Molecular and Genetic Testing Labs Need to Know to Succeed with Commercialization of Their Precision Medicine Products

 What Molecular and Genetic Testing Labs Need to Know to Succeed with Commercialization of Their Precision Medicine Products

One of healthcare’s unheralded stories is good news for molecular and genetic testing laboratories, along with hospital and health system labs that already have instruments capable of performing these tests! Day-by-day, ever more physicians begin to include elements of precision medicine in their clinical practice, thus requiring them to use molecular and genetic tests.

 Physician demand for these tests is robust and will continue to increase for a powerful reason: patients want the benefits from a diagnostic test that delivers a more accurate diagnosis while pointing the doctor to the right therapy that will benefit the patient while minimizing side effects.

These are just two reasons why it is imperative that every clinical laboratory and pathology group have a strategy for how it will serve precision medicine. Tests in support of precision medicine will be the fastest-growing sector of laboratory medicine for years to come. That’s why labs need a strategy that addresses these elements:

  1. Which type of precision medicine tests will the lab emphasize?
  2. Can it run these tests on existing lab analyzers, or will it need to acquire new instruments?
  3. Are there existing physician-champions of precision medicine in the lab’s service area who are respected as clinical leaders and willing to share their patient care successes with colleagues?
  4. Can the lab profitably collaborate/partner with labs and companies that already have proven assays, robust informatics capabilities, and similar tools needed to provide tests that support precision medicine?
  5. Are there payers in the lab’s regional market that have existing coverage guidelines for the types of precision medicine tests the lab wants to provide? Are the targeted types of precision medicine tests covered by existing managed care contracts?

These important questions are among the topics covered in the "What Molecular and Genetic Testing Labs Need to Know to Succeed with Commercialization of Their Precision Medicine Products" webinar hosted by Dark Daily.

Featured XIFIN Speaker

Kyle Fetter
VP & General Manager of Diagnostic Services
XIFIN, Inc.

DARK Daily is an e-briefing service providing up-to-the minute news of relevance for anyone working in diagnostic medicine, from clinical laboratories and pathology groups to lab industry suppliers and diagnostic technology companies. DARK Daily is part of The Dark Intelligence Group, Inc. and is dedicated to bringing useful business and management intelligence to laboratory managers, pathologists and diagnostic executives. Dark’s recognized expertise in the strategic direction of laboratory medicine and the management of laboratories is available through DARK Daily, The Dark Report, free White Papers, Lab Resource Directory, the Executive War College on Laboratory and Pathology Management, Lab Quality Confab, and strategic consulting services.

Details

Dark Daily Webinar
EVENT TYPE:
Webinar
WHEN:
Mar 22, 2017
EVENT WEBSITE:
www.darkdaily.com/audio-conferences
XIFIN SPEAKER(S):

Kyle Fetter, VP & General Manager of Diagnostic Services, XIFIN, Inc.

SPEAKER(S):

Don Rule, Founder and Chief Executive Officer, Translational Software

Yoav Sibony, Vice President of Sales and Marketing, Translational Software

VIEW RECORDING

This webinar is hosted by Dark Daily. For additional webinar details and pricing, click the button below.

View Now